Trial Profile
Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Inodiftagene-vixteplasmid (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Sponsors Anchiano Therapeutics Israel; BioCancell Therapeutics
- 09 Feb 2018 Results presented in a BioCancell Therapeutics Media Release.
- 09 Feb 2018 According to a BioCancell Therapeutics media release, final analysis of this trial were presented at the 2018 ASCO Genitourinary Cancers Symposium.
- 15 Nov 2017 According to a BioCancell Therapeutics media release, Patients are being followed for up to 2 years, and the median follow-up at the time of the analysis is approximately 18 months.